In his presentation Dr. Greb, president and CEO of Focus Clinical Drug Development GmbH (Neuss, Germany), summarizes pertinent issues of early phase development of biologicals.

He points out that careful analysis of the molecular situation is required and that the relevant target structures and species need to be chosen in preclinical evaluation of the compounds activity.

You may wish to download Dr. Greb’s presentation for your personal use. To order a complimentary copy of Dr. Greb’s presentationon specific challenges in human pharmacology trials with biologicals enter your email address below and press the submit button:

A detailed complimentary copy of Dr. Greb’s presentation can be ordered by entering your email address below and pressing the submit button:

“FOCUS Immunology Laboratories Heidelberg” offer testing of biomarkers for immune cell functions tailored to the specific requirements of a given clinical trial.

For further information please contact Dr. Eddy Bruyns at eddy.bruyns@focus-cdd.com.